🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Lots to learn at #NCCN2025 with Maddie Klugman, MD MS - grateful for the opportunity from Johns Hopkins Hematology and Oncology Fellowship

Most viewed in the last 7 days from JAMA Oncology: Survivors of childhood cancer undergo considerable accelerated aging in terms of early onset and excess risk of chronic health conditions. ja.ma/4iTrJ1O

Presented at #ACC25: In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full trial results:

A night at the orchestra with our Chief Fellow Michelle Ferreira and Matthias Holdhoff !🎻Beyond the clinic and lab, our fellows and faculty share a passion for music and medicine. #LifeAtHopkins #OncologyFellowship #MoreThanMedicine 🎶

The first manuscript from my fellowship research investigating apCAF biology in mouse PDAC tumors is now on bioRxiv!

🔬 Excited to share our review on adjuvant immune-based strategies for pancreas cancer. With new data emerging, the key to success may lie in combinatorial approaches & personalized therapies. 👉 Read more: mdpi.com/3258352 #CancerResearch #PancreaticCancer

Original Article: Assessment of a Polygenic Risk Score in Screening for Prostate Cancer (BARCODE1 study) nej.md/44jT8Fn Editorial: A Polygenic Risk Score in Practice nej.md/4jv4JWJ #Oncology

🆕article in press: Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study G Curigliano MD PhD doi.org/10.1016/j.anno…

A lot is happening in breast cancer! ASCENT-04 reports improvement in PFS for sacituzumab + pembro vs TPC+pembro in 1L mTNBC, & DESTINY-Breast09 reports improved PFS for TDXd+P vs THP in 1L metastatic HER2+ breast cancer! Nice to see new options for our pts!

🆕article in press: Copenhagen Prospective Personalized Oncology (CoPPO) – Impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting doi.org/10.1016/j.anno…

Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy. ja.ma/42HMCWB

This study found low resumption of endocrine therapy and imaging post-pregnancy in breast cancer patients, with a 19% incidence of subsequent events over 10 years. ja.ma/3RQ3ntG

Brilliant discussion by Javier Cortes MD PhD on APHINITY If adjuvant treatments decrease distant events, is OS benefit really needed to be seen to start using therapies? APHINITY took 11.3 yrs to be able to see OS benefit. #ESMOBreast25 ESMO - Eur. Oncology

#ASCO25 #OncTwitter #crcsm NEW: Randomized trial of exercise vs health ed in people w/ colon cancer post adjuvant chemo: disease-free (HR 0.72; 6.4% abs diff at 5y) & overall (HR 0.63; 7.1% abs diff at 8y) survival improved w/ exercise! NNT ~14. ACTUALLY tolerable. 🏆 #OncoAlert

With synchronous publication in NEJM, Fatima Cardoso ABC Global Alliance shows Elinzanetant reduces vasomotor symptoms (hot flashes) for patients on ET with HR+ BC #ASCO25

Congratulations to my mentor (and fellow early bird) Dean Hosgood!

Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III #ColonCancer: Results of the Phase II Randomized LEANOX Trial. Read the full article. brnw.ch/21wTDPO

The gift that keeps on giving. Another important publication from the POSITIVE trial regarding Breastfeeding in women who gave birth. @Oncoalert #bcsm ascopubs.org/doi/10.1200/JC…

I wrote for #ASCOConnection about the duality of oncology—the quiet heaviness of being both oncologist and dad. The weight doesn’t go away, but you get better at carrying it—and finding meaning in the middle of the mess. What keeps you grounded? ASCO lnkd.in/gxZ5Duuv